Dutch Life Sciences conference Financing life sciences development and growth by M&A, IPO or partnering strategy

December 2023



Introduction



Petra van Zuijlen Partner, PwC NL



Stijn Spitaels Partner, PwC NL



Guillaume Jetten CFO, Symeres




Matthew Wagener Director of Finance Operations, NewAmsterdam Pharma




- 1. Introduction
- 2. Market Context
- 3. Panel discussion
- 4. Q&A

Setting the scene: the type of financing typically evolves through the lifecycle of a business...



...as do the different types of providers of equity and debt





Other

Different types of private market investors have differing characteristics and behaviors


AUM of European private markets funds by type

€tn, 2013-2022






European healthcare deal volumes are high but have shifted towards smaller transactions...



DLSC Panel Discussion

...supported by resilient early stage investments

Early stage European VC investments (pre seed, seed, series A) €bn, Q3 2019 – Q3 2023




Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023

Not exclusively

healthcare


This is in the context of rising interest rates, but also economic uncertainty and geopolitical tensions



Investors are bullish looking forward, seeing opportunities for PE & VC due to increased stability and lower expected interest rates

Forecasted interest rate by central bank

%, Q1 '23 - Q4 '25




PwC

European PE & VC dry powder has grown to c.350bn in 2022, increasing the pressure to invest

Total AUM of European private markets funds

€bn, 2013 - 2022






They will typically come under investor pressure to deploy this capital and put it to work!

DLSC Panel Discussion Source: Invest Europe, PwC Analysis

PwC

Panel Discussion

pwc



Dutch Life Sciences



Stijn Spitaels Partner, PwC NL



Guillaume Jetten CFO, Symeres



Matthew Wagener Director of Finance Operations, NewAmsterdam Pharma

Panel members

Thank you

pwc.com

© 2023 PwC. All rights reserved. Not for further distribution without the permission of PwC. "PwC" refers to the network of member firms of PricewaterhouseCoopers International Limited (PwCIL), or, as the context requires, individual member firms of the PwC network. Each member firm is a separate legal entity and does not act as agent of PwCIL or any other member firm. PwCIL does not provide any services to clients. PwCIL is not responsible or liable for the acts or omissions of any of its member firms nor can it control the exercise of their professional judgment or bind them in any way. No member firm is responsible or liable for the acts or omissions of any other member firm nor can it control the exercise of another member firm's professional judgment or bind another member firm or PwCIL in any way.